Conference abstractPublished 20 Jun 2018
Discovery of GPR119/DPP4 dual-target compounds as anti-diabetic candidates
Peking Union Medical College | China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Glucagon like peptide-1 (GLP-1) plays a vital role in glucose homeostasis and sustaining β-cell function. Currently there are two major methods to enhance endogenous GLP-1 activity; inhibiting dipeptidyl peptidase-4 (DPP4) or activating G protein-coupled receptor 119 (GPR119). Here we designed and synthesized a series of xanthine derivatives as potent dual ligands targeting DPP-IV and GPR119 through an approach of the merged pharmacophores of GPR119 agonists and DPP-IV inhibitor linagliptin. Among these derivatives, we validate a compound, HBK001 which can both inhibit DPP4 and activate GPR119 ex and in vivo. We show that HBK001 can promote glucose-stimulated insulin secretion in mouse primary islets in a concentration-dependent manner. A single administration of HBK001 in ICR mice can increase plasma incretins (GLP-1 and GIP) levels much more efficiently than DPP4 inhibitor linagliptin. Long-term treatment of HBK001 in KKAy mice can ameliorate hyperglycemia as well as improve glucose tolerance, while linagliptin fails to achieve such glucose-lowing effects despite inhibiting 95% of serum DPP4 activity. Furthermore, HBK001 can improve islet morphology in diabetic KKAy mice, increase β-cell mass by promoting proliferation and up-regulating genes involved in β-cell proliferation and function. Thus, we have identified, designed and synthesized a novel GPR119/DPP4 dual-target compound, HBK001, which represents a promising therapeutic candidate for type 2 diabetes, especially for patients who are insensitive to current DPP4 inhibitors..
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Yi Huan”